EGFR and non-small cell lung carcinoma: Sunvozertinib and zongertinib are likely to be incorporated into National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines as first- or second-line options for EGFR exon 20 NSCLC, where therapeutic choices were previously limited to amivantamab (Rybrevant®) or mobocertinib (Exkivity®) respectively, both of which had ORRs <40 %.